Stockreport

Pandion Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

Pandion Therapeutics Inc.  (PAND) 
PDF - Enrollment and dosing complete in Phase 1a clinical trial of PT101; top-line results expected early 2021- PT627 systemic PD-1 agonist development candidate nominated; [Read more]